Also known as: Sotyktu
Deucravacitinib is an oral TYK2 inhibitor marketed as Sotyktu for moderate-to-severe plaque psoriasis in adults. It is considered a first-in-class TYK2 inhibitor by the U.S. FDA and has approvals across multiple regions including the U.S., EU, and Australia. It is prescription-only.
Alumis reported that 54% of psoriasis patients achieved complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, with 75% achieving PASI 90. The company plans to submit an NDA for envudeucitinib in Q4 2026.
Real-world and trial data show ixekizumab and deucravacitinib provide durable efficacy in psoriatic arthritis. Ixekizumab achieved high remission rates and drug retention over 24 months, while deucravacitinib improved outcomes across multiple disease domains in the phase III POETYK PsA-2 trial.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.
The FDA is set to make approval decisions on five drug applications in March 2026, including treatments for psoriatic arthritis, dry eye disease, hypothalamic obesity, cholestatic pruritus, and a rare genetic disorder.
Takeda announced positive Phase 3 results for zasocitinib in adults with moderate-to-severe plaque psoriasis, meeting all 44 endpoints. The company is also conducting a Phase 3 trial in pediatric patients.
Drug Hunter has opened nominations for the 2025 Molecules of the Year following the announcement of the final Molecules of the Month for 2025. Eligible molecules must have been first disclosed or had a major update in 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07508488 |
Deucravacitinib in the Treatment of Cicatricial Alopecias |
RECRUITING | PHASE2 |
| NCT07352566 |
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07280702 |
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease |
NOT_YET_RECRUITING | PHASE4 |
| NCT07256015 |
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy |
RECRUITING | |
| NCT07116967 |
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) |
RECRUITING | PHASE3 |
| NCT07017699 |
A Study to Assess Deucravacitinib Safety in Pregnancy |
RECRUITING | |
| NCT07013838 |
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07000630 |
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis |
TERMINATED | NA |
| NCT06979453 |
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis |
RECRUITING | PHASE3 |
| NCT06973291 |
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis |
COMPLETED | PHASE3 |
